This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Bioavailability Remove Genotype Remove In-Vitro Related Topics
In-Vivo Protein Licensing Genetics Development Drugs Vaccine Vaccination Clinical Trials Medicine More Related Topics >
article thumbnail

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. which will remain a key shareholder. SciNeuro Pharmaceuticals. in a statement. . Libra Therapeutics.

Marketing 52
Marketing In-Vivo Protein In-Vitro 52
article thumbnail

Clinical study first step towards treating respiratory syncytial virus 

Drug Discovery World

OCTOBER 18, 2022

EDP-323 is supported by in vitro data demonstrating a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B, with consistent potency across a range of RSV clinical isolates in various cell types. . Context . The trial . EDP-323 .

In-Vitro 52
In-Vitro Genotype Bioavailability Clinical Trials 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024